Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Urologic Surgery Associates
mi
from
Baltimore, MD
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Urologic Surgery Associates
mi
from
Baltimore, MD
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Drs. Werner, Murdock and Francis PA Urology Associates
mi
from
Greenbelt, MD
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Drs. Werner, Murdock and Francis PA Urology Associates
mi
from
Greenbelt, MD
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Kansas City Urology Care
mi
from
Kansas City, MO
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Kansas City Urology Care
mi
from
Kansas City, MO
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Siteman Cancer Center
mi
from
St. Louis, MO
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Nevada Urology
mi
from
Reno, NV
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Nevada Urology
mi
from
Reno, NV
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Lawrenceville Urology
mi
from
Trenton, NJ
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Lawrenceville Urology
mi
from
Trenton, NJ
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Accumed Research Associates
mi
from
Garden City, NY
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Accumed Research Associates
mi
from
Garden City, NY
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Staten Island Urological Research, PC
mi
from
Staten Island, NY
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Staten Island Urological Research, PC
mi
from
Staten Island, NY
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Oregon Urology Specialists
mi
from
Springfield, OR
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Oregon Urology Specialists
mi
from
Springfield, OR
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Urological Associates of Lancaster
mi
from
Lancaster, PA
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Urological Associates of Lancaster
mi
from
Lancaster, PA
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Triangle Urological Group
mi
from
Pittsburgh, PA
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Triangle Urological Group
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Salt Lake Research, PLLC
mi
from
Salt Lake City, UT
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Salt Lake Research, PLLC
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
David Reed, M.D.
mi
from
Seattle, WA
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
David Reed, M.D.
mi
from
Seattle, WA
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Madigan Army Medical Center Urology Service
mi
from
Tacoma, WA
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Madigan Army Medical Center Urology Service
mi
from
Tacoma, WA
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Gundersen Lutheran Medical Center
mi
from
LaCrosse, WI
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Gundersen Lutheran Medical Center
mi
from
LaCrosse, WI
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Southern Interior Medical Research Inc.
mi
from
Kelowna,
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Southern Interior Medical Research Inc.
mi
from
Kelowna,
Click here to add this to my saved trials
Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS
Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS and Machine Learning to Better Manage the Disease
Status: Enrolling
Updated:  6/7/2016
Ummc Msgcc
mi
from
Baltimore, MD
Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS
Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS and Machine Learning to Better Manage the Disease
Status: Enrolling
Updated: 6/7/2016
Ummc Msgcc
mi
from
Baltimore, MD
Click here to add this to my saved trials
Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS
Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS and Machine Learning to Better Manage the Disease
Status: Enrolling
Updated:  6/7/2016
Ummc Msgcc
mi
from
Baltimore, MD
Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS
Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS and Machine Learning to Better Manage the Disease
Status: Enrolling
Updated: 6/7/2016
Ummc Msgcc
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Status: Enrolling
Updated:  6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Status: Enrolling
Updated: 6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Prostate Cancer After Non-Myeloablative Conditioning
Status: Enrolling
Updated:  6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Prostate Cancer After Non-Myeloablative Conditioning
Status: Enrolling
Updated: 6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Ultrasound Imaging in Finding Prostate Cancer in Patients Undergoing Surgery
A Pilot Evaluation of the Efficacy of HistoScanning™ in Predicting the Presence and Location of Prostate Cancer in Men Undergoing Radical Prostatectomy
Status: Enrolling
Updated:  6/16/2016
Smilow Comprehensive Prostate Cancer Center
mi
from
New York, NY
Ultrasound Imaging in Finding Prostate Cancer in Patients Undergoing Surgery
A Pilot Evaluation of the Efficacy of HistoScanning™ in Predicting the Presence and Location of Prostate Cancer in Men Undergoing Radical Prostatectomy
Status: Enrolling
Updated: 6/16/2016
Smilow Comprehensive Prostate Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Alaska Urology Institute Alaska Clinical Research Center
mi
from
Anchorage, AK
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Alaska Urology Institute Alaska Clinical Research Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
University of Colorado, Denver Medical Campus
mi
from
Aurora, CO
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
University of Colorado, Denver Medical Campus
mi
from
Aurora, CO
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Urology Center of Colorado
mi
from
Denver, CO
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Urology Center of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Urological Research Network
mi
from
Hialeah, FL
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Urological Research Network
mi
from
Hialeah, FL
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Lakeland Regional Health Systems
mi
from
Lakeland, FL
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Lakeland Regional Health Systems
mi
from
Lakeland, FL
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
University of Miami Miller School of Medicine
mi
from
Miami, FL
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Spectrum Health Medical Group
mi
from
Grand Rapids, MI
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Spectrum Health Medical Group
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Delaware Valley Urology, LLC
mi
from
Voorhees, NJ
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Delaware Valley Urology, LLC
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Carolina Urology Partners
mi
from
Gastonia, NC
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Carolina Urology Partners
mi
from
Gastonia, NC
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Lancaster Urology
mi
from
Lancaster, PA
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Lancaster Urology
mi
from
Lancaster, PA
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
University of Vermont Medical Center
mi
from
Burlington, VT
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
University of Vermont Medical Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Virginia Urology
mi
from
Richmond, VA
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Virginia Urology
mi
from
Richmond, VA
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Univ of Washington
mi
from
Seattle, WA
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated:  6/20/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]
Status: Enrolling
Updated: 6/20/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Anaheim, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Laguna Hills, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
Murrieta, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
Murrieta, CA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
mi
from
San Luis Obispo, CA
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials